Osteoporosis International

, Volume 17, Issue 4, pp 521–526

Relationship of circulating MMP–2, MMP–1, and TIMP–1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women

  • X.-H. Luo
  • L.-J. Guo
  • P.-F. Shan
  • H. Xie
  • X.-P. Wu
  • H. Zhang
  • X.-Z. Cao
  • L.-Q. Yuan
  • E.-Y. Liao
Original Article



Osteoblast-derived matrix metalloproteinase (MMP)–2, MMP–1 and tissue inhibitor of metalloproteinase (TIMP)–1 have been shown to play a role in bone metabolism by degrading the bone matrix.


The present study was performed to investigate the relationships between serum MMP–2, MMP–1, or TIMP–1 levels and bone mineral density (BMD), as well as bone biochemical markers, in 297 Chinese postmenopausal women aged 42–80 years.


We found a significant negative weak correlation between MMP–2 and BMD at various skeletal regions. After adjustment for age and BMI, the correlation with BMD at the femoral neck and total hip disappeared. Multiple linear stepwise regression analysis showed that MMP–2 was not a determinant factor for BMD. The significant positive correlations between MMP–2 and bone cross-linked N–telopeptides of type I collagen (NTX), alkaline phosphatase (BAP), and osteocalcin (OC) and were found, and remained significant after adjustment for age and BMI. Moreover, serum MMP–2 concentrations were significantly higher in postmenopausal women with osteoporosis than in age-matched normal controls. There were no significant correlations between MMP–1, TIMP–1 and BMD. There were no significant relationships between MMP–1 and BAP, OC, and NTX. The associations between TIMP–1 and BAP and OC were not specific and constant.


In conclusion, our results suggest that circulating MMP–2 and markers of bone turnover are correlated, and serum MMP–2 levels may rise with increase in bone turnover.


Bone biochemical marker Bone mineral density Matrix metalloproteinase Postmenopausal women 


  1. 1.
    Rifas L, Fausto A, Scott MJ, Avioli LV, Welgus HG (1994) Expression of metalloproteinase and tissue inhibitor of metalloptroteinase in human osteoblast-like cells: metalloproteinase biosythesis. Endocrinology 134:213–221CrossRefPubMedGoogle Scholar
  2. 2.
    Meikle MC, Bord S, Hembry RM, Compston J, Croucher PI, Reynolds JJ (1992) Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines. J Cell Sci 103:1093–1099PubMedGoogle Scholar
  3. 3.
    Rifas L, Halstead LR, Peck WA, Avioli LV, Welgus HG (1989) Human osteoblasts in vitro secrete tissue inhibitor of metalloproteinases and gelatinase but not interstitial collagenase as major cellular products. J Clin Invest 84:686–694PubMedCrossRefGoogle Scholar
  4. 4.
    Vaes G (1988) Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation, and mode of action of osteoclasts. Clin Orthop 231:239–271PubMedGoogle Scholar
  5. 5.
    Chambers TJ, Fuller K (1985) Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. J Cell Sci 76:155–165PubMedGoogle Scholar
  6. 6.
    Holliday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL (1997) Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 272:22053–22058PubMedCrossRefGoogle Scholar
  7. 7.
    Westermarck J, Kahari V (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781–792PubMedGoogle Scholar
  8. 8.
    Liao EY, Luo XH (2001) Effect of 17β–estradiol on the expression of matrix metalloproteinase–1, –2 and tissue inhibitor of metalloproteinase–1 in human osteoblast-like cell cultures. Endocrine 15:291–295CrossRefPubMedGoogle Scholar
  9. 9.
    Meikle MC, Bord S, Hembry RM, Reynolds JJ (1995) The synthesis of collagenase, gelatinase–A (72 kDa) and –B (95 kDa), and TIMP–1 and –2 by human osteoblasts from normal and arthritic bone. Bone 17:255–260CrossRefPubMedGoogle Scholar
  10. 10.
    Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S (1999) Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 878:212–227PubMedCrossRefGoogle Scholar
  11. 11.
    Liao EY, Wu XP, Deng XG, Huang G, Zhu XP, Long ZF, Wang WB, Tang WL, Zhang H (2002) Age-related bone mineral density, accumulated bone loss rate and prevalence of osteoporosis at multiple skeletal sites in chinese women. Osteoporos Int 13:669–676CrossRefPubMedGoogle Scholar
  12. 12.
    Liao EY, Wu XP, Luo XH, Zhang H, Dai RC, Huang G, Wang WB (2003) Establishment and evaluation of bone mineral density reference databases appropriate for diagnosis and evaluation of osteoporosis in Chinese women. J Bone Miner Metab 21:184–192PubMedCrossRefGoogle Scholar
  13. 13.
    Wu XP, Liao EY, Zhang H, Shan PF, Cao XZ, Liu SP (2004) Establishment of BMD reference plots and determination of peak BMD at multiple skeletal regions in mainland Chinese women and the diagnosis of osteoporosis. Osteoporos Int 15:71–79CrossRefPubMedGoogle Scholar
  14. 14.
    Kelly TL (1992) Study protocol QDR reference databases. Hologic, Bedford, Mass.Google Scholar
  15. 15.
    Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedCrossRefGoogle Scholar
  16. 16.
    Chailurkit LO, Ongphiphadhanakul B, Piaseu N, Saetung S, Rajatanavin R (2001) Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory. Clin Chem 47:1083–1088PubMedGoogle Scholar
  17. 17.
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fracture in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536PubMedCrossRefGoogle Scholar
  18. 18.
    Tchetverikov I, Ronday HK, Van El B, Kiers GH, Verzijl N, TeKoppele JM, Huizinga TW, DeGroot J, Hanemaaijer R (2004) MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 63:881–883CrossRefPubMedGoogle Scholar
  19. 19.
    Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY (2000) Matrix metalloproteinase–9 and tissue inhibitor metalloproteinase–1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75:43–47CrossRefPubMedGoogle Scholar
  20. 20.
    Tziakas DN, Chalikias GK, Parissis JT, Hatzinikolaou EI, Papadopoulos ED, Tripsiannis GA, Papadopoulou EG, Tentes IK, Karas SM, Chatseras DI (2004) Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 94:269–277CrossRefPubMedGoogle Scholar
  21. 21.
    Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP (2004) Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP–1 and TIMP–2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99:271–279CrossRefPubMedGoogle Scholar
  22. 22.
    La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S (2004) Zymographic detection and clinical correlations of MMP–2 and MMP–9 in breast cancer sera. Br J Cancer 90:1414–1421CrossRefPubMedGoogle Scholar
  23. 23.
    Perry HM 3rd, Bernard M, Horowitz M, Miller DK, Fleming S, Baker MZ, Flaherty J, Purushothaman R, Hajjar R, Kaiser FE, Patrick P, Morley JE (1998) The effect of aging on bone mineral metabolism and bone mass in Native American women. J Am Geriatr Soc 46:1418–1422PubMedGoogle Scholar
  24. 24.
    Nakaoka D, Sugimoto T, Kaji H, Kanzawa M, Yano S, Yamauchi M, Sugishita T, Chihara K (2001) Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women. Osteoporos Int 12:548–554CrossRefPubMedGoogle Scholar
  25. 25.
    Filanti C, Dickson GR, Di Martino D, Ulivi V, Sanguineti C, Romano P, Palermo C, Manduca P (2000) The expression of metalloproteinase–2, –9, and –14 and of tissue inhibitors–1 and –2 is developmentally modulated during osteogenesis in vitro, the mature osteoblastic phenotype expressing metalloproteinase–14. J Bone Miner Res 15:2154–2168PubMedCrossRefGoogle Scholar
  26. 26.
    Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM (2003) The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859–867PubMedCrossRefGoogle Scholar
  27. 27.
    Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T (1998) Regulation of matrix metalloproteinases (MMP–2, –3, –9, and –13) by interleukin–1 and interleukin–6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 139:1338–1345CrossRefPubMedGoogle Scholar
  28. 28.
    Ichinose Y, Migita K, Nakashima T, Kawakami A, Aoyagi T, Eguchi K (2000) Effects of bisphosphonate on the release of MMP–2 from cultured human osteoblasts. Tohoku J Exp Med 192:111–118CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2005

Authors and Affiliations

  • X.-H. Luo
    • 1
  • L.-J. Guo
    • 1
  • P.-F. Shan
    • 1
  • H. Xie
    • 1
  • X.-P. Wu
    • 1
  • H. Zhang
    • 1
  • X.-Z. Cao
    • 1
  • L.-Q. Yuan
    • 1
  • E.-Y. Liao
    • 1
  1. 1.Institute of Endocrinology & MetabolismThe Second Xiangya Hospital of Central South UniversityChangshaPeoples’s Republic of China

Personalised recommendations